特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
市場調査レポート
商品コード
656148

結核治療薬市場規模、シェア、動向分析:疾患別(活動性結核、潜伏性結核)、治療別(第一次、第二次)、地域別動向、競合環境、セグメント予測

Tuberculosis (TB) Drugs/Therapeutics Market Size, Share & Trends Analysis Report by Disease Type (Active TB, Latent TB), By Therapy (First-Line, Second-Line), By Region, Competitive Landscape, And Segment Forecasts, 2018 - 2025

出版日: | 発行: Grand View Research, Inc. | ページ情報: 英文 140 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.58円
結核治療薬市場規模、シェア、動向分析:疾患別(活動性結核、潜伏性結核)、治療別(第一次、第二次)、地域別動向、競合環境、セグメント予測
出版日: 2018年05月29日
発行: Grand View Research, Inc.
ページ情報: 英文 140 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界の結核治療薬市場について調査し、市場の現状と成長予測、疾患別、治療別、地域別動向、および市場に参入する企業のプロファイルなどをまとめています。

第1章 調査方法と範囲

第2章 エグゼクティブサマリー

第3章 市場変数、動向、範囲

  • 市場セグメンテーションと範囲
    • 促進因子分析
    • 阻害因子分析
  • 浸透度と成長見通しマッピング
  • SWOT分析
  • 業界分析

第4章 治療別市場と動向分析

  • 動向分析
  • 第一次治療
  • 第二次治療

第5章 疾患タイプ別予測と動向分析

  • 潜伏性結核
  • 活動性結核

第6章 地域別予測と動向分析

  • 市場シェア
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ

第7章 競合環境

  • 戦略枠組み
  • 市場参入分類
  • 企業プロファイル
    • Johnson & Johnson Services, LLC
    • Lupin
    • Novartis AG
    • Macleods Pharmaceuticals Ltd.
    • 大塚製薬株式会社
    • Pfizer

第8章 市場見通し

  • 市場シナリオ
  • パイプライン分析
図表

List of Tables

  • TABLE 1 North America tuberculosis Drugs/Therapeutics market, by country, 2014 - 2025 (USD Million)
  • TABLE 2 North America tuberculosis Drugs/Therapeutics market, by disease type, 2014 - 2025 (USD Million)
  • TABLE 3 North America tuberculosis Drugs/Therapeutics market, by therapy type, 2014 - 2025 (USD Million)
  • TABLE 4 U.S. tuberculosis Drugs/Therapeutics market, by disease type, 2014 - 2025 (USD Million)
  • TABLE 5 U.S. tuberculosis Drugs/Therapeutics market, by therapy type, 2014 - 2025 (USD Million)
  • TABLE 6 Canada tuberculosis Drugs/Therapeutics market, by disease type, 2014 - 2025 (USD Million)
  • TABLE 7 Canada tuberculosis Drugs/Therapeutics market, by therapy type, 2014 - 2025 (USD Million)
  • TABLE 8 Europe tuberculosis Drugs/Therapeutics market, by country, 2014 - 2025 (USD Million)
  • TABLE 9 Europe tuberculosis Drugs/Therapeutics market, by disease type, 2014 - 2025 (USD Million)
  • TABLE 10 Europe tuberculosis Drugs/Therapeutics market, by therapy type, 2014 - 2025 (USD Million)
  • TABLE 11 Germany tuberculosis Drugs/Therapeutics market, by disease type, 2014 - 2025 (USD Million)
  • TABLE 12 Germany tuberculosis Drugs/Therapeutics market, by therapy type, 2014 - 2025 (USD Million)
  • TABLE 13 France tuberculosis Drugs/Therapeutics market, by disease type, 2014 - 2025 (USD Million)
  • TABLE 14 France tuberculosis Drugs/Therapeutics market, by therapy type, 2014 - 2025 (USD Million)
  • TABLE 15 U.K. tuberculosis Drugs/Therapeutics market, by disease type, 2014 - 2025 (USD Million)
  • TABLE 16 U.K. tuberculosis Drugs/Therapeutics market, by therapy type, 2014 - 2025 (USD Million)
  • TABLE 17 Statistics for TB in high burden countries in APAC region, 2016
  • TABLE 18 Asia Pacific tuberculosis Drugs/Therapeutics market, by country, 2014 - 2025 (USD Million)
  • TABLE 19 Asia Pacific tuberculosis Drugs/Therapeutics market, by disease type, 2014 - 2025 (USD Million)
  • TABLE 20 Asia Pacific tuberculosis Drugs/Therapeutics market, by therapy type, 2014 - 2025 (USD Million)
  • TABLE 21 India tuberculosis Drugs/Therapeutics market, by disease type, 2014 - 2025 (USD Million)
  • TABLE 22 India tuberculosis Drugs/Therapeutics market, by therapy type, 2014 - 2025 (USD Million)
  • TABLE 23 China tuberculosis Drugs/Therapeutics market, by disease type, 2014 - 2025 (USD Million)
  • TABLE 24 China tuberculosis Drugs/Therapeutics market, by therapy type, 2014 - 2025 (USD Million)
  • TABLE 25 Philippines tuberculosis Drugs/Therapeutics market, by disease type, 2014 - 2025 (USD Million)
  • TABLE 26 Philippines tuberculosis Drugs/Therapeutics market, by therapy type, 2014 - 2025 (USD Million)
  • TABLE 27 Latin America TB cases, 2013
  • TABLE 28 Latin America tuberculosis Drugs/Therapeutics market, by country, 2014 - 2025 (USD Million)
  • TABLE 29 Latin America tuberculosis Drugs/Therapeutics market, by disease type, 2014 - 2025 (USD Million)
  • TABLE 30 Latin America tuberculosis Drugs/Therapeutics market, by therapy type, 2014 - 2025 (USD Million)
  • TABLE 31 Brazil tuberculosis Drugs/Therapeutics market, by disease type, 2014 - 2025 (USD Million)
  • TABLE 32 Brazil tuberculosis Drugs/Therapeutics market, by therapy type, 2014 - 2025 (USD Million)
  • TABLE 33 Mexico tuberculosis Drugs/Therapeutics market, by disease type, 2014 - 2025 (USD Million)
  • TABLE 34 Mexico tuberculosis Drugs/Therapeutics market, by therapy type, 2014 - 2025 (USD Million)
  • TABLE 35 Africa tuberculosis Drugs/Therapeutics market, by country, 2014 - 2025 (USD Million)
  • TABLE 36 Africa tuberculosis Drugs/Therapeutics market, by disease type, 2014 - 2025 (USD Million)
  • TABLE 37 Africa tuberculosis Drugs/Therapeutics market, by therapy type, 2014 - 2025 (USD Million)
  • TABLE 38 South Africa tuberculosis Drugs/Therapeutics market, by disease type, 2014 - 2025 (USD Million)
  • TABLE 39 South Africa tuberculosis Drugs/Therapeutics market, by therapy type, 2014 - 2025 (USD Million)
  • TABLE 40 Nigeria tuberculosis Drugs/Therapeutics market, by disease type, 2014 - 2025 (USD Million)
  • TABLE 41 Nigeria tuberculosis Drugs/Therapeutics market, by therapy type, 2014 - 2025 (USD Million)

List of Figures

  • FIG. 1 Market summary 2016, (USD Million)
  • FIG. 2 Market research process
  • FIG. 3 Information procurement
  • FIG. 4 Primary research pattern
  • FIG. 5 Market research approaches
  • FIG. 6 Value chain based sizing & forecasting
  • FIG. 7 QFD modelling for market share assessment
  • FIG. 8 Market trends & outlook
  • FIG. 9 Market segmentation & scope
  • FIG. 10 Market driver relevance analysis (Current & future impact)
  • FIG. 11 Average treatment cost, per case (2016 USD), in the U.S.
  • FIG. 12 Penetration & growth prospect mapping
  • FIG. 13 Tuberculosis Drugs/Therapeutics market - PESTLE analysis
  • FIG. 14 Porter's five forces analysis
  • FIG. 15 Drugs/Therapeutics in development for tuberculosis
  • FIG. 16 Tuberculosis Drugs/Therapeutics market, Therapy outlook: Key takeaways
  • FIG. 17 Tuberculosis Drugs/Therapeutics market: Therapy movement analysis
  • FIG. 18 Treatment of tuberculosis in adult and children
  • FIG. 19 First-line Drugs/Therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 20 Treatment of tuberculosis with second-line Drugs/Therapeutics
  • FIG. 21 Second-line therapy market, 2014 - 2025 (USD Million)
  • FIG. 22 Tuberculosis Drugs/Therapeutics market: Disease type movement analysis
  • FIG. 23 LTBI treatment regimen
  • FIG. 24 Latent TB Drugs/Therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 25 Active TB Drugs/Therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 26 Regional market place: Key takeaways
  • FIG. 27 Tuberculosis Drugs/Therapeutics market: Regional outlook, 2014 & 2025
  • FIG. 28 North America tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 29 U.S. tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 30 Canada tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD million)
  • FIG. 31 Europe tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 32 Germany tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 33 France tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 34 U.K. tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 35 Asia Pacific tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 36 India tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 37 China Tuberculosis Drugs/Therapeutics Market, 2014 - 2025 (USD Million)
  • FIG. 38 Philippines Tuberculosis Drugs/Therapeutics Market, 2014 - 2025 (USD Million)
  • FIG. 39 Latin America tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 40 Brazil tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 41 Mexico tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 42 Africa tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 43 South Africa tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 44 Nigeria tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 45 Strategy framework
  • FIG. 46 SWOT analysis (Johnson & Johnson)
  • FIG. 47 SWOT analysis (Lupin)
  • FIG. 48 SWOT analysis (Novartis AG)
  • FIG. 49 SWOT analysis (Macleods Pharmaceuticals Ltd)
  • FIG. 50 SWOT Analysis (Otsuka Pharmaceuticals)
  • FIG. 51 SWOT analysis (Pfizer)
目次
Product Code: GVR-2-68038-500-7

The global tuberculosis drugs/therapeutics (TB) market size is expected to reach USD 1.38 billion by 2025, according to a new report by Grand View Research, Inc., registering a CAGR of 5.2% during the forecast period. Rising prevalence of Multidrug Resistant (MDR) tuberculosis and HIV-tuberculosis co-infection is likely to drive the market during the forecast period. According to WHO, in 2017, the annual incidence of tuberculosis (TB) in India was 2.8 million cases, with an estimated 147,000 multi-drug resistant cases. India has the second highest estimation of HIV-TB co-infection cases per year, i.e., 87,000.

The TB drugs market is expected to witness high growth in the coming years due to development of shorter-regimen drug treatments and availability of private and public funding. The Nix-TB trial currently being conducted by TB Alliance in conjunction with Janssen Pharmaceuticals involves a combination of drugs, pretomanid, linezolid, and bedaquiline, which promises a cure for Extensively Drug Resistant (XDR) form of the disease within 6-9 months.

Apart from competitive dynamics, license agreements among players are providing opportunities for emerging drug manufacturers to grow in this space. In September 2015, Dishman Group received a license agreement from Janssen Pharmaceutica NV, subsidiary of Johnson & Johnson Services, LLC to produce the active pharmaceutical ingredient (API) for the drug Sirturo (bedaquiline), intended for MDR TB treatment. Dishman, apart from being an API supplier for Janssen's novel drug, is now listed as a licensed API manufacturer with the EMA, USFDA, and several Asian regulatory authorities.

Further key findings from the report suggest:

Collaborative efforts among international organizations and pharmaceutical players are spurring drug development and treatment access, which is expected to propel the growth of the tuberculosis drugs market

In March 2015, a collaboration between the United States Agency for International Development (USAID) and the Janssen Global Services, LLC was undertaken to provide the drug bedaquiline free of cost to eligible MDR-tuberculosis patients

Based on disease type, the active tuberculosis drugs segment accounted for the largest share of 87.3% in 2016. If undiagnosed, latent tuberculosis has the potential to transform to the active form, which has led countries in Europe and North America to focus on early diagnosis and preventive measures

Based on therapy type, second-line therapy drugs led the market with a share of 60.4% in 2016. Rising incidence and higher treatment cost structure of MDR tuberculosis, coupled with increasing treatment access, is spurring market growth

Regionally, Asia Pacific held a major market share and is expected to retain its dominance during the forecast period due to high disease incidence and gradual improvement in patient medication adherence rates

Europe is likely to witness significant growth over the next decade due to high MDR-TB burden, along with improved focus on LTBI treatment drugs

Some of the key players in the tuberculosis drugs market are Johnson & Johnson (J&J) Services, Lupin, Pfizer, Novartis AG, Macleods Pharmaceuticals Limited, and Otsuka Pharmaceutical Co., Ltd.

Table of Contents

Chapter 1 Research Methodology & Scope

  • 1.1 Information Procurement
    • 1.1.1 Purchased database:
    • 1.1.2 GVR's internal database
  • 1.2 Research Methodology
  • 1.3 Geographic scope & assumptions
  • 1.4 Region-wise market calculation
    • 1.4.1 Region-wise market: Base estimates
    • 1.4.2 Global market: CAGR calculation
  • 1.5 Region-based segment share calculation
  • 1.6 List of Secondary Sources

Chapter 2 Executive Summary

  • 2.1 Market Snapshot

Chapter 3 Market Variables, Trends & Scope

  • 3.1 Market segmentation & scope
    • 3.1.1 Market Drivers Analysis
      • 3.1.1.1 Global plan against drug-resistant TB drives diagnosis and treatment enrollment
      • 3.1.1.2 HIV burden fuels LTBI case counts
    • 3.1.2 Market Restraints Analysis
      • 3.1.2.1 High drug cost
      • 3.1.2.2 Poor regulation and lack of awareness in developing countries
  • 3.2 Penetration & growth prospect mapping
  • 3.3 Tuberculosis Drugs/Therapeutics Market - SWOT Analysis, By Factor (political & legal, economic and technological)
  • 3.4 Industry Analysis - Porter's

Chapter 4 Tuberculosis Drugs/Therapeutics Market: Therapy Type & Trend Analysis

  • 4.1 Tuberculosis Drugs/Therapeutics Market: Therapy Type Movement Analysis
    • 4.1.1 First-Line Therapy
      • 4.1.1.1 First-line therapy market, 2014 - 2025 (USD Million)
    • 4.1.2 Second-Line Therapy
      • 4.1.2.1 Second-line therapy market, 2014 - 2025 (USD Million)

Chapter 5 Tuberculosis Drugs/Therapeutics Market: Disease Type & Trend Analysis5

  • 5.1 Latent TB
    • 5.1.1 Latent TB Drugs/Therapeutics market, 2014 - 2025 (USD Million)
  • 5.2 Active TB
    • 5.1.2 Active TB Drugs/Therapeutics market, 2014 - 2025 (USD Million)

Chapter 6 Market Categorization 2: Regional Estimates & Trend Analysis

  • 6.1 Tuberculosis Drugs/Therapeutics Market Share, By Region, 2014 & 2025
  • 6.2 North America
    • 6.2.1. North America tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
    • 6.2.2 U.S.
      • 6.2.2.1 U.S. tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
    • 6.2.3 Canada
      • 6.2.3.1 Canada tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD million)
  • 6.3 Europe
    • 6.3.1 Germany
      • 6.3.1.1 Germany tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
    • 6.3.2 France
      • 6.3.2.1 France tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
    • 6.3.3 UK
      • 6.3.3.1 UK tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
  • 6.4 Asia Pacific
    • 6.4.1 Asia Pacific tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
    • 6.4.2 India
      • 6.4.2.1 India tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
    • 6.4.3 China
      • 6.4.3.1 China tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
    • 6.4.4 Philippines
      • 6.4.4.1 Philippines tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
  • 6.5 Latin America
    • 6.5.1 Latin America tuberculosis Drugs/Therapeutics market, 2014 - 2026 (USD Million)
    • 6.5.2 Brazil
      • 6.5.2.1 Brazil tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
    • 6.5.3 Mexico
      • 6.5.3.1 Mexico tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
  • 6.6 Middle East & Africa
    • 6.6.1 Africa tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
    • 6.6.2 South Africa
      • 6.6.2.1 South Africa tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
    • 6.6.3 Nigeria
      • 6.6.3.1 Nigeria tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)

Chapter 7 Competitive Landscape

  • 7.1 Strategy framework
  • 7.2 Market participation categorization
  • 7.3 Company Profiles
    • 7.3.1 Johnson & Johnson Services, LLC
      • 7.3.1.1 Company overview
      • 7.3.1.2 Financial performance
      • 7.3.1.3 Product overview
      • 7.3.1.4 Business strategies
      • 7.3.1.5 SWOT analysis (Johnson & Johnson Services, LLC)
    • 7.3.2 Lupin
      • 7.3.2.1 Company overview
      • 7.3.2.2 Financial performance
      • 7.3.2.3 Product Overview
      • 7.3.2.4 Business growth strategies
      • 7.3.2.5 SWOT analysis (Lupin)
    • 7.3.3 Novartis AG
      • 7.3.3.1 Company overview
      • 7.3.3.2 Financial performance
      • 7.3.3.3 Product overview
      • 7.3.3.4 Business strategies
      • 7.3.3.5 SWOT analysis (Novartis AG)
    • 7.3.4 Macleods Pharmaceuticals Ltd.
      • 7.3.4.1 Company overview
      • 7.3.4.2 Financial performance
      • 7.3.4.3 Product overview
      • 7.3.4.4 Business strategies
      • 7.3.4.5 SWOT analysis (Macleods Pharmaceuticals Ltd)
    • 7.3.5 Otsuka Pharmaceutical Co., Ltd.
      • 7.3.5.1 Company overview
      • 7.3.5.2 Financial performance
      • 7.3.5.3 Product Overview
      • 7.3.5.4 Business strategies
      • 7.3.5.5 SWOT analysis (Otsuka Pharmaceuticals)
    • 7.3.6 Pfizer
      • 7.3.6.1 Company overview
      • 7.3.6.2 Financial performance
      • 7.3.6.3 Product overview
      • 7.3.6.4 Business Strategies
      • 7.3.6.5 SWOT analysis (Pfizer)

Chapter 8 Market Outlook

  • 7.1 Market Scenario
  • 7.2 Pipeline Analysis
    • 7.2.1 Repurposed Drugs/Therapeutics
    • 7.2.2 Current Regimen Trials
    • 7.2.3 Promising Therapies
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.